TY - JOUR
T1 - Evaluation of Patient Willingness to Adopt Remote Digital Monitoring for Diabetes Management
AU - Oikonomidi, Theodora
AU - Ravaud, Philippe
AU - Cosson, Emmanuel
AU - Montori, Victor
AU - Tran, Viet Thi
N1 - Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/1/13
Y1 - 2021/1/13
N2 - Importance: Patients will decide whether to adopt remote digital monitoring (RDM) for diabetes by weighing its health benefits against the inconvenience it may cause. Objective: To identify the minimum effectiveness patients report they require to adopt 36 different RDM scenarios. Design, Setting, and Participants: This survey study was conducted among adults with type 1 or type 2 diabetes living in 30 countries from February to July 2019. Exposures: Survey participants assessed 3 randomly selected scenarios from a total of 36. Scenarios described different combinations of digital monitoring tools (glucose, physical activity, food monitoring), duration and feedback loops (feedback in consultation vs real-time telefeedback by a health care professional or by artificial intelligence), and data handling modalities (by a public vs private company), reflecting different degrees of RDM intrusiveness in patients' personal lives. Main Outcomes and Measures: Participants assessed the minimum effectiveness for 2 diabetes-related outcomes (reducing hypoglycemic episodes and preventing ophthalmologic complications) for which they would adopt each RDM (from much less effective to much more effective than their current monitoring). Results: Of 1577 individuals who consented to participate, 1010 (64%; 572 [57%] women, median [interquartile range] age, 51 [37-63] years, 524 [52%] with type 1 diabetes) assessed at least 1 vignette. Overall, 2860 vignette assessments were collected. In 1025 vignette assessments (36%), participants would adopt RDM only if it was much more effective at reducing hypoglycemic episodes compared with their current monitoring; in 1835 assessments (65%), participants would adopt RDM if was just as or somewhat more effective. The main factors associated with required effectiveness were food monitoring (β = 0.32; SE, 0.12; P =.009), real-time telefeedback by a health care professional (β = 0.49; SE, 0.15; P =.001), and perceived intrusiveness (β = 0.36; SE, 0.06; P <.001). Minimum required effectiveness varied among participants; 34 of 36 RDM scenarios (94%) were simultaneously required to be just as or less effective by at least 25% of participants and much more effective by at least 25% of participants. Results were similar for participant assessments of scenarios regarding the prevention of ophthalmologic complications. Conclusions and Relevance: The findings of this study suggest that patients require greater health benefits to adopt more intrusive RDM modalities, food monitoring, and real-time feedback by a health care professional. Patient monitoring devices should be designed to be minimally intrusive. The variability in patients' requirements points to a need for shared decision-making..
AB - Importance: Patients will decide whether to adopt remote digital monitoring (RDM) for diabetes by weighing its health benefits against the inconvenience it may cause. Objective: To identify the minimum effectiveness patients report they require to adopt 36 different RDM scenarios. Design, Setting, and Participants: This survey study was conducted among adults with type 1 or type 2 diabetes living in 30 countries from February to July 2019. Exposures: Survey participants assessed 3 randomly selected scenarios from a total of 36. Scenarios described different combinations of digital monitoring tools (glucose, physical activity, food monitoring), duration and feedback loops (feedback in consultation vs real-time telefeedback by a health care professional or by artificial intelligence), and data handling modalities (by a public vs private company), reflecting different degrees of RDM intrusiveness in patients' personal lives. Main Outcomes and Measures: Participants assessed the minimum effectiveness for 2 diabetes-related outcomes (reducing hypoglycemic episodes and preventing ophthalmologic complications) for which they would adopt each RDM (from much less effective to much more effective than their current monitoring). Results: Of 1577 individuals who consented to participate, 1010 (64%; 572 [57%] women, median [interquartile range] age, 51 [37-63] years, 524 [52%] with type 1 diabetes) assessed at least 1 vignette. Overall, 2860 vignette assessments were collected. In 1025 vignette assessments (36%), participants would adopt RDM only if it was much more effective at reducing hypoglycemic episodes compared with their current monitoring; in 1835 assessments (65%), participants would adopt RDM if was just as or somewhat more effective. The main factors associated with required effectiveness were food monitoring (β = 0.32; SE, 0.12; P =.009), real-time telefeedback by a health care professional (β = 0.49; SE, 0.15; P =.001), and perceived intrusiveness (β = 0.36; SE, 0.06; P <.001). Minimum required effectiveness varied among participants; 34 of 36 RDM scenarios (94%) were simultaneously required to be just as or less effective by at least 25% of participants and much more effective by at least 25% of participants. Results were similar for participant assessments of scenarios regarding the prevention of ophthalmologic complications. Conclusions and Relevance: The findings of this study suggest that patients require greater health benefits to adopt more intrusive RDM modalities, food monitoring, and real-time feedback by a health care professional. Patient monitoring devices should be designed to be minimally intrusive. The variability in patients' requirements points to a need for shared decision-making..
UR - http://www.scopus.com/inward/record.url?scp=85099896068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099896068&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2020.33115
DO - 10.1001/jamanetworkopen.2020.33115
M3 - Article
C2 - 33439263
AN - SCOPUS:85099896068
SN - 2574-3805
VL - 4
JO - JAMA network open
JF - JAMA network open
IS - 1
M1 - e2033115
ER -